{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:23:20Z","timestamp":1794349400077,"version":"4.9.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCATS U54NS148312"],"award-info":[{"award-number":["NCATS U54NS148312"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NICHD R01HD112908"],"award-info":[{"award-number":["NICHD R01HD112908"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["MRFF2015970"],"award-info":[{"award-number":["MRFF2015970"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC20150180"],"award-info":[{"award-number":["NHMRC20150180"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002721","name":"Charcot-Marie-Tooth Association","doi-asserted-by":"publisher","award":["SR-202601"],"award-info":[{"award-number":["SR-202601"]}],"id":[{"id":"10.13039\/100002721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["1060929"],"award-info":[{"award-number":["1060929"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117568","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:37:12Z","timestamp":1790069832000},"page":"117568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PXT3003: Lessons for therapeutic development in Charcot-Marie-Tooth disease type 1A and related neuropathies"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-623X","authenticated-orcid":false,"given":"Joshua","family":"Burns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117568_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-025-00679-2","article-title":"Charcot-Marie-Tooth disease and related neuropathies","volume":"12","author":"Burns","year":"2026","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.117568_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/jnnp-2021-328483","article-title":"Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease","volume":"93","author":"Yiu","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.isci.2026.117568_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13023-014-0201-x","article-title":"Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy","volume":"9","author":"Chumakov","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117568_bib4","article-title":"A phase III clinical trial of PXT3003 in Chinese patients with Charcot-Marie-Tooth disease type 1A","volume":"29","author":"Liu","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.117568_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209752","article-title":"Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)","volume":"14","author":"Prukop","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117568_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-014-0199-0","article-title":"An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A","volume":"9","author":"Attarian","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117568_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1212\/01.WNL.0000156517.00615.A3","article-title":"Reliability and validity of the CMT neuropathy score as a measure of disability","volume":"64","author":"Shy","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2026.117568_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the overall neuropathy limitations scale","volume":"77","author":"Graham","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.isci.2026.117568_bib9","article-title":"Ascorbic acid for the treatment of Charcot-Marie-Tooth disease","volume":"2015","author":"Gess","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.isci.2026.117568_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","article-title":"A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A","volume":"16","author":"Attarian","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117568_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.isci.2026.117568_bib12","author":"Taylor"},{"key":"10.1016\/j.isci.2026.117568_bib13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMsr1414226","article-title":"The proposed rule for U.S. clinical trial registration and results submission","volume":"372","author":"Zarin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117568_bib14","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","article-title":"Trial Reporting in ClinicalTrials.gov - The Final Rule","volume":"375","author":"Zarin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117568_bib15","first-page":"Mr000011","article-title":"Time to publication for results of clinical trials","volume":"2024","author":"Showell","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.isci.2026.117568_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117568_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102881","article-title":"Safety, efficacy, and distal nerve Schwann cell biodistribution in mice and NHPs to support translation of AAV9 RNAi therapy for CMT1A","volume":"37","author":"Stavrou","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.isci.2026.117568_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mus.27250","article-title":"Minimal important differences and self-identifying treatment response in chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Rajabally","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.isci.2026.117568_bib19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/mus.28478","article-title":"Minimal Clinically Important Differences in Measuring Treatment Effects in CIDP: History, Current Use, Limitations, and Prospects","volume":"72","author":"Rajabally","year":"2025","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.isci.2026.117568_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1474-4422(11)70025-4","article-title":"Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial","volume":"10","author":"Pareyson","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.isci.2026.117568_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13023-015-0293-y","article-title":"A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment","volume":"10","author":"Mandel","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.isci.2026.117568_bib22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ana.23572","article-title":"Validation of the Charcot\u2013Marie\u2013Tooth disease pediatric scale as an outcome measure of disability","volume":"71","author":"Burns","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.isci.2026.117568_bib23","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207963","article-title":"Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure","volume":"102","author":"Mandarakas","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.isci.2026.117568_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","article-title":"High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial","volume":"32","author":"Finkel","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117568_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117568_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117568_bib27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ana.26633","article-title":"Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints","volume":"93","author":"Reilly","year":"2023","journal-title":"Ann. Neurol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226029470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:35:03Z","timestamp":1794346503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226029470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226029470"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117568","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PXT3003: Lessons for therapeutic development in Charcot-Marie-Tooth disease type 1A and related neuropathies","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117568"}}